|
|
Comment Period Now Open for Addition of Recovered Plasma Specification to QSEAL
February 16, 2010
In accordance with the procedures for developing a PPTA Voluntary Standard, the public comment period will be open for 60 days, until April 16, 2010.
|
|
more >>
|
| |
|
|
Kedrion Earns International Quality Certification For Manufacturing Lifesaving Plasma-Derived Therapies
February 5, 2010
ANNAPOLIS, MD (February 5, 2010) - The Plasma Protein Therapeutics Association (PPTA) announced today that Kedrion is the sixth company to be certified through its international Quality Standards of Excellence, Assurance, and Leadership (QSEAL) Program, which evaluates manufacturers of plasma protein therapies.
|
|
more >>
|
| |
|
|
PPTA Launches New Website Tool
September 23, 2009
ANNAPOLIS, MD (September 23, 2009) – Visitors to DonatingPlasma.org can more easily find their local plasma donation center now with an improved search feature. The Plasma Protein Therapeutics Association (PPTA), which developed the website to raise awareness of plasma donation, unveils the tool today, seeking to build on the importance of providing up-to-date information to donors who provide plasma needed to manufacture life-saving therapies.
|
|
more >>
|
| |
|
|
Plasma Protein Therapeutics Association Urges CMS for Appropriate Hospital Outpatient Reimbursement
August 11, 2009
ANNAPOLIS, MD—Aug. 11, 2009—The Plasma Protein Therapeutics Association (PPTA) supports the favorable recommendation of average sales price (ASP) + 6 percent for reimbursement of separately paid drugs and biologics in the hospital outpatient setting made by the Centers for Medicare and Medicaid Services’ (CMS) Advisory Panel on Ambulatory Payment Classification (APC) at its August 5-7 meeting, although third party data maintains that ASP +12 percent is the appropriate reimbursement level.
|
|
more >>
|
| |
|
|
Texans Help Produce as well as Benefit from Lifesaving Therapies
August 1, 2009
ANNAPOLIS, MD—August 1, 2009—This month, Texans are recognized for their outstanding contributions to lifesaving therapies that treat critically ill individuals and for their donations of the blood component, plasma, in one of 48 specialized plasma collection centers in the state that make the creation of the unique therapies possible. In June, the House of Representatives of the 81st Texas Legislature recognized August 2009 as “Plasma Protein Therapies Month” in the Lone Star State, helping raise awareness of the rare, genetic diseases treated with the therapies and valuing the contributions of voluntary plasma donors across the state.
|
|
more >>
|
| |
|
|
Plasma Protein Therapeutics Association Supports Patient-Centered Outcomes Research Act of 2009
July 21, 2009
ANNAPOLIS, MD—July 21, 2009—The Plasma Protein Therapeutics Association (PPTA) strongly supports S.1213, the Patient-Centered Outcomes Research Act of 2009, a bill that would establish a nonprofit corporation called the Patient-Centered Outcomes Research Institute to contract with appropriate Federal agencies or the private sector to conduct comparative effectiveness research (CER).
|
|
more >>
|
| |
|
|
FOLLOW-ON BIOLOGICS LEGISLATION MUST NOT PUT PATIENTS WITH RARE DISEASES AT RISK
June 16, 2009
ANNAPOLIS, MD—June 16, 2009—A white paper commissioned by the Plasma Protein Therapeutics Association (PPTA) to evaluate the effects of impending follow-on biologics legislation concludes that Congress should exempt plasma protein therapies unless safety and efficacy in a follow-on therapy can be clinically established.
|
|
more >>
|
| |
|
|
ABC’S “EXTREME MAKEOVER: HOME EDITION” HELPS FAMILY FACING RARE IMMUNE DEFICIENCY DISEASE TREATED WITH PLASMA-DERIVED THERAPY
May 10, 2009
Primary immunodeficiency diseases (PIDD) is a rare disease that affects the body’s ability to fight infection and that is treated with the biological therapy, immune globulin (Ig), that can only be made from donated plasma. Today, the Cerda Family of Las Vegas, Nevada, who have two children with a PIDD, will be the lucky recipients of a new home thanks to the ABC television show, “Extreme Makeover: Home Edition.” The new home will provide a better environment, free of mold, for the family.
|
|
more >>
|
| |
|
|
Plasma Protein Therapies in the Politico
April 29, 2009
In a big step to raise awareness for the need to protect patient access to plasma protein therapies, PPTA launched an 8-page advertorial in the Politico newspaper that also appears on www.politico.com/preservepatientaccess.
|
|
more >>
|
| |
|
|
Statement on the Safety of Plasma Protein Therapies and Swine Influenza Virus
April 28, 2009
PPTA member companies are committed to providing safe and effective therapies and PPTA understands that patients who rely on these often life-saving therapies may have concerns about the possible transmission of Swine Influenza Virus through them in view of the recent outbreak in humans. Therapies produced by PPTA members remain safe and available.
|
|
more >>
|
| |
|
|
CIDP Treated with Plasma-derived Therapy
April 24, 2009
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a debilitating, progressive neurological disorder that results in muscle weakness and fatigue and can severely impair motor skills. According to the GBS/CIDP Foundation International, CIDP affects two to seven individuals per 100,000 worldwide. The rare disease is treated with intravenous immune globulin (IVIG), a plasma-derived therapy that replaces vital missing antibodies in a person’s plasma and that is manufactured by member companies of the Plasma Protein Therapeutics Association (PPTA).
|
|
more >>
|
| |
|
|
PPTA Backgrounder
March 23, 2009
Variant Creutzfeldt Jakob Disease (vCJD)
and the Safety of Plasma Protein
|
|
more >>
|
| |
|
|
Glossary of Terms
March 23, 2009
Transmissible Spongiform Encephalopathic (TSE) Disease
|
|
more >>
|